X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Synthetic Antibiotics Way To Go For Critical Chronic Issues

Content Team by Content Team
5th January 2024
in Drug Development, News
Developing Drugs That Target Multidrug-Resistant Bacteria

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Antimicrobial Resistance- AMR as it is referred to, is rising, and an AMR review that was commissioned by the UK Government has gone on to predict that by 2050, an additional 10 million people may as well succumb to drug-resistant infections every year. The development when it comes to new antibiotics those that can be used as a last resort when other drugs happen to be ineffective happens to be a crucial area of study when it comes to healthcare researchers across the world.

A new synthetic antibiotic, which happens to be developed by University of Liverpool researchers, has gone on to show more effectiveness than the established drugs against superbugs like MRSA. The new study, which was published in in the European Journal of Medicinal Chemistry, goes on to demonstrate the potent activity of the antibiotic teixobactin against the bacterial biofilms. Biofilms happen to be clusters of bacteria that get attached to a surface and/or to each other, which happen to be associated with certain critical chronic infections in humans.

This work is constructed with pioneering research by Dr. Ishwar Singh, from the University of Liverpool, an expert in antimicrobial drug discovery as well as development and medicinal chemistry. A team of researchers which had been led by Dr. Singh went on to create simplified synthetic versions when it comes to natural molecule teixobactin, which gets used by producer bacteria in order to kill other bacteria within the soil. They have gone on to test a unique library of synthetic versions of the antibiotic that’s indeed game-changing, thereby optimizing major traits of the drug so as to enhance its efficacy and safety teamed with enabling it to be produced inexpensively at scale.

For the latest study, the researchers went on to design and also synthesised highly potent teixobactin analogues; however, they swapped out the major bottleneck building block L-allo-enduracididine with the commercially and low-cost simplified building blocks available, like non-proteogenic amino acids. Due to this, the analogues are now pretty impactful against a broad range of bacterial pathogens that are resistant, including bacterial isolates from patients as well as bacterial biofilms. This happens to be yet another pivotal measure when it comes to adapting the natural teixobactin molecule so as to make it apt for human use.

According to Dr. Ishwar Singh, Teixobactin molecules happen to be having the capacity to offer new treatment choices against multidrug-resistant bacterial as well as biofilm-related infections to enhance and save lives across the world. He adds that their study goes on to offer quite a promising base for further research and also brings about avenues so as to discover the application of teixobactin across numerous health-related biofilm contexts such as surgical site infections, implant-related surgeries, as well as cystic fibrosis patients.

It is well to be noted that this work that has been done happens to be funded by Innovate UK, the Rosetrees Trust, as well as the Department of Health and Social Care. Besides the University of Liverpool team, it also involves Singapore Eye Research Institute researchers, Nanyang Technological University from Singapore, the University of Utrecht from the Netherlands, the University of Lincoln from the UK, and the University of Ghent, Belgium.

Previous Post

The Rising Challenges In The Path of Global Pharma In 2024

Next Post

7 Potential Drivers of The Life Sciences Landscape In 2024

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

7 Potential Drivers of The Life Sciences Landscape In 2024

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In